The new drugs for hepatitis B treatment are changing day by day, and the new drugs for hepatitis B treatment mainly contain the following two categories: first, direct antiviral drugs, the mechanism of action is to target the virus and interfere with the process of inhibiting HBV replication; second, indirect antiviral drugs, the mechanism of action is to target the human immune system to attack the HBV virus. Direct antiviral drugs mainly include the following categories: 1, TDF precursor drugs, the mechanism of action is easier to enter the hepatocytes of TDF modifiers; 2, siRNA, the mechanism of action to interfere with and destroy viral RNA; 3, entry inhibitors, the mechanism of action to interfere with the entry of HBV into the liver cells; 4, capsid inhibitors, the mechanism of action to interfere with the formation of viral DNA protein; 5, hepatitis B surface antigen inhibitors, the mechanism of action to interfere with the hepatitis B surface antigen inhibitors. The mechanism of action interferes with the production of hepatitis B surface antigen; 6. antisense RNA, the mechanism of action binds to viral mRNA to prevent the formation of viral protein; 7. ribonuclease inhibitors, the mechanism of action inhibits the degradation of viral RNA. Indirect antiviral drugs mainly contain therapeutic vaccines, the mechanism of action vaccine technology to activate the human immune system therapeutic approach.